Dr Rachel Hemsley, Global Head of Business Development at Nottingham-based DMPK provider XenoGesis, has been appointed to the Advisory Board of BioPartner, the trade organisation for internationalising life sciences companies.
BioPartner works closely with UK bioscience sector stakeholders including regional networks, national trade associations, and government departments; to promote UK expertise and to provide cost-effective access to overseas partners and new markets for UK-based organisations.
Founded in 2011 and based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK Due Diligence and modelling & simulation for human PK and dose prediction.
Dr Hemsley, who is responsible for identifying and managing a portfolio of potential and new clients and building strong relationships with external companies at XenoGesis, will join Paul Cronin, Alasdair Stamps, Will Watson, Dave Mead and Hakan Goker on BioPartner’s Advisory Board.
Commenting on the appointment, Dr Hemsley said: “I am delighted to be joining the Advisory Board at BioPartner and look forward to using my expertise to support its services to the bioscience industry. I will bring 12 years’ sector experience to the Board, including early stage technology development, securing investment funding, licensing early stage healthcare technology and setting up new companies.”
Lin Bateson, Chief Executive of BioPartner, said: “We have established a significant UK presence at several international conferences over the past 10 years, and we have created many networking and business opportunities for UK companies. Having such experienced Business Development professionals as Advisors helps to ensure our services to industry are appropriate and the best they can be.”